NCT02221960 - A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

July 3, 2017

Study Completion Date

July 3, 2017

Conditions

Recurrent or Metastatic Solid Tumors

Interventions

BIOLOGICAL

MEDI6383

Subjects will receive MEDI6383 until disease progression or adverse event.

BIOLOGICAL

MEDI6383 and MEDI4736

Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.

Trial Locations (8)

Research Site, Parkville

Research Site, New York

Research Site, Washington D.C.

Research Site, Nashville

Research Site, Chicago

Research Site, La Jolla

Research Site, Portland

Research Site, New Haven